Email Alert RSS
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2024  > 
MAO Mingyi, JIANG Fang, XIANG Yang. Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2024-0135
Citation: MAO Mingyi, JIANG Fang, XIANG Yang. Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2024-0135
shu

Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia

doi: 10.12290/xhyxzz.2024-0135

  • 1 National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;

  • 2 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National Key R&D Program of China (2023YFC2705802)

  • Available Online: 2024-04-24
    Abstract
  • Gestational trophoblastic neoplasia (GTN) can be classified into low-risk and high-risk patients based on the FIGO staging and scoring system. High-risk patients have a higher risk of resistance to single-agent chemotherapy and require combination chemotherapy. However, there are still some high-risk patients who develop resistance to combination chemotherapy or experience recurrence after cure. These patients exhibit strong heterogeneity, and subsequent treatment poses significant challenges, attracting considerable attention in recent years. Therefore, this article provides a review of the risk factors and treatment strategies for high-risk resistant and recurrent GTN patients, aiming to provide a basis for early identification of high-risk patients and their precise treatment.
    • FullText(HTML)
  • loading
    • References(32)
  • [1] 中国抗癌协会妇科肿瘤专业委员会.妊娠滋养细胞疾病诊断与治疗指南2021年版)[J].中国癌症杂志, 2021, 31(6):520-532.
    [2] Kohorn E. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease:description and critical assessment[J]. International Journal of Gynecologic Cancer, 2001, 11(1).
    [3] Ngan H Y S, Seckl M J, Berkowitz R S, et al. Diagnosis and management of gestational trophoblastic disease:2021 update[J]. Int J Gynaecol Obstet, 2021, 155 Suppl 1(Suppl 1):86-93.
    [4] Escobar P F, Lurain J R, Singh D K, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy[J]. Gynecol Oncol, 2003, 91(3):552-557.
    [5] Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2006, 16(3):1432-1438.
    [6] Li Y, Kong Y, Wan X, et al. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ＞/=5[J]. Oncologist, 2021, 26(12):e2209-e2216.
    [7] Jareemit N, Therasakvichya S, Freitas F, et al. EMACO for treatment of gestational trophoblastic neoplasia:A multinational multicenter study[J]. Gynecol Oncol, 2023, 170:114-122.
    [8] Yang J, Xiang Y, Wan X, et al. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV):A report based on our 10-year clinical experiences[J]. Gynecol Oncol, 2016, 143(1):68-72.
    [9] Kong Y, Zong L, Cheng H, et al. Management and risk factors of recurrent gestational trophoblastic neoplasia:An update from 2004 to 2017[J]. Cancer Med, 2020, 9(7):2590-2599.
    [10] Mao Y, Wan X, Lv W, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen[J]. Int J Gynaecol Obstet, 2007, 98(1):44-47.
    [11] Lu W G, Ye F, Shen Y M, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia:a clinical analysis of 54 patients[J]. Int J Gynecol Cancer, 2008, 18(2):357-362.
    [12] Wang M, Shen L, Xu X, et al. Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia[J]. BioMed Research International, 2021, 2021:1-8.
    [13] Wang J, Short D, Sebire N J, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)[J]. Ann Oncol, 2008, 19(9):1578-1583.
    [14] Feng F, Xiang Y, Wan X, et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia[J]. Ann Oncol, 2011, 22(7):1588-1594.
    [15] Veras E, Kurman R J, Wang T-L, et al. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases[J]. International Journal of Gynecological Pathology, 2017, 36(2):146-153.
    [16] Bolze P A, Patrier S, Massardier J, et al. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes[J]. Int J Gynecol Cancer, 2017, 27(3):554-561.
    [17] Huang M, Pinto A, Castillo R P, et al. Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma[J]. J Clin Oncol, 2017, 35(27):3172-3174.
    [18] Ghorani E, Kaur B, Fisher R A, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110):2343-2345.
    [19] You B, Bolze P A, Lotz J P, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy:Cohort B of the TROPHIMMUN phase 2 trial[J]. Gynecol Oncol, 2023, 168:62-67.
    [20] Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01):a single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(11):1609-1617.
    [21] Wang X, Cang W, Liu X, et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia:a multicenter, retrospective study[J]. EClinicalMedicine, 2023, 59:101974-101974.
    [22] Hennah L, Seckl M, Ghorani E. Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy[J]. Int J Gynecol Cancer, 2023, 33(3):414-419.
    [23] Doumplis D, Al-Khatib K, Sieunarine K, et al. Short communication:A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006[J]. BJOG:An International Journal of Obstetrics& Gynaecology, 2007, 114(9):1168-1171.
    [24] Fang J, Wang S, Han X, et al. Role of adjuvant hysterectomy in management of high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2012, 22(3):509-514.
    [25] Sugrue R, Foley O, Elias K M, et al. Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease[J]. Gynecol Oncol, 2021, 160(2):445-449.
    [26] Feng F, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia[J]. Gynecol Oncol, 2009, 113(3):312-315.
    [27] Cao Y, Xiang Y, Feng F, et al. Surgical Resection in the Management of Pulmonary Metastatic Disease of Gestational Trophoblastic Neoplasia[J]. International Journal of Gynecological Cancer, 2009, 19(4):798-801.
    [28] Kanis M J, Lurain J R. Pulmonary Resection in the Management of High-Risk Gestational Trophoblastic Neoplasia[J]. Int J Gynecol Cancer, 2016, 26(4):796-800.
    [29] Zhao L, Qin Y, Ma D, et al. Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia:A retrospective study[J]. Gynecol Oncol, 2022, 167(1):37-41.
    [30] Kong Y, Wang W, Lin J, et al. Management and Predictors of Treatment Failure in Patients with Chemo-Resistant/Relapsed Gestational Trophoblastic Neoplasia with Lung Metastasis[J]. J Clin Med, 2022, 11(24).
    [31] Manchana T, Ittiwut C, Mutirangura A, et al. Targeted therapies for rare gynaecological cancers[J]. Lancet Oncol, 2010, 11(7):685-693.
    [32] Worley M J, Jr., Elias K M, Horowitz N S, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab:A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute[J]. Gynecol Oncol, 2018, 148(1):5-11.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (5) PDF downloads(1) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return